Table 2.
MRPS23 status in primary tumours and lymph node metastases according to MRPS23/CEP17 ratio, mean MRPS23 and amplification status
| Mean MRPS23/tumour cell, primary tumours | Marginal homogeneity test | ||||
|---|---|---|---|---|---|
| < 4 | ≥ 4, < 6 | ≥ 6 | Total | ||
| Mean MRPS23/tumour cell, lymph nodes | |||||
| < 4 | 125 (97) | 4 (40) | 1 (20) | 130 | p = 0.637 |
| ≥ 4, < 6 | 3 (2) | 5 (50) | 2 (40) | 10 | |
| ≥ 6 | 1 (1) | 1 (10) | 2 (40) | 4 | |
| Total | 129 | 10 | 5 | 144 | |
| MRPS23/CEP17 ratio, primary tumours | ||||
|---|---|---|---|---|
| < 2 | ≥ 2 | Total | McNemar test | |
| MRPS23/CEP17 ratio, lymph nodes | ||||
| < 2 | 130 (99) | 3 (23) | 133 | p = 0.625 |
| ≥ 2 | 1 (1) | 10 (76) | 11 | |
| Total | 131 | 13 | 144 | |
| Amplification status, primary tumours | ||||
|---|---|---|---|---|
| MRPS23− | MRPS23+ | Total | McNemar test | |
| Amplification status, lymph nodes | ||||
| MRPS23−a | 128 (98) | 4 (29) | 132 | p = 0.688 |
| MRPS23+b | 2 (2) | 10 (71) | 12 | |
| Total | 130 | 14 | 144 | |
aMRPS23/CEP17 < 2 and mean MRPS23 < 6
bMRPS23/CEP17 ≥ 2 and/or mean MRPS23 ≥ 6